The effect and mechanism of dopamine D1 receptors on the proliferation of osteosarcoma cells

Gao, Jun; Zhang, Chao; Gao, Feng; Li, Hongzhu

doi:10.1007/s11010-017-2951-y

Cited by 17 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, dopamine inhibits osteosarcoma cell proliferation via downregulation of ERK1/2 and PI3K/AKT pathways, controlled by D1 receptors. 248 In the case of gastric cancer cells, DA inhibits migration and invasion, potentially via inhibition of the EGFR-AKT pathway. 249 In gastric cancer, increased expression of D2R negatively correlates with patient survival.…”

Section: Classical Central Nervous System Neurotransmitters (Dopaminementioning

confidence: 99%

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

Cervantes‐Villagrana

Albores-García

Cervantes-Villagrana

et al. 2020

Sig Transduct Target Ther

161

112

View full text Add to dashboard Cite

Normal cells are hijacked by cancer cells forming together heterogeneous tumor masses immersed in aberrant communication circuits that facilitate tumor growth and dissemination. Besides the well characterized angiogenic effect of some tumor-derived factors; others, such as BDNF, recruit peripheral nerves and leukocytes. The neurogenic switch, activated by tumor-derived neurotrophins and extracellular vesicles, attracts adjacent peripheral fibers (autonomic/sensorial) and neural progenitor cells. Strikingly, tumor-associated nerve fibers can guide cancer cell dissemination. Moreover, IL-1β, CCL2, PGE 2 , among other chemotactic factors, attract natural immunosuppressive cells, including T regulatory (Tregs), myeloid-derived suppressor cells (MDSCs), and M2 macrophages, to the tumor microenvironment. These leukocytes further exacerbate the aberrant communication circuit releasing factors with neurogenic effect. Furthermore, cancer cells directly evade immune surveillance and the antitumoral actions of natural killer cells by activating immunosuppressive mechanisms elicited by heterophilic complexes, joining cancer and immune cells, formed by PD-L1/PD1 and CD80/CTLA-4 plasma membrane proteins. Altogether, nervous and immune cells, together with fibroblasts, endothelial, and bone-marrow-derived cells, promote tumor growth and enhance the metastatic properties of cancer cells. Inspired by the demonstrated, but restricted, power of anti-angiogenic and immune cell-based therapies, preclinical studies are focusing on strategies aimed to inhibit tumor-induced neurogenesis. Here we discuss the potential of anti-neurogenesis and, considering the interplay between nervous and immune systems, we also focus on anti-immunosuppression-based therapies. Small molecules, antibodies and immune cells are being considered as therapeutic agents, aimed to prevent cancer cell communication with neurons and leukocytes, targeting chemotactic and neurotransmitter signaling pathways linked to perineural invasion and metastasis.

show abstract

Section: Classical Central Nervous System Neurotransmitters (Dopaminementioning

confidence: 99%

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

Cervantes‐Villagrana

Albores-García

Cervantes-Villagrana

et al. 2020

Sig Transduct Target Ther

161

112

View full text Add to dashboard Cite

show abstract

“…DRD1 are expressed in osteosarcoma cells, treating DRD1 agonist SKF38393 (10 μM) can inhibit the proliferation of osteosarcoma in vitro . The effect of SKF38393 on the proliferation of osteosarcoma is related to down-regulation of the ERK1/2 and PI3K-Akt pathways by activating DRD1 87. A screening of ~1,000 biological active compounds implied that a selective agonist of DRD1, A77636 (2 μM), could inhibit the proliferation of breast cancer cells in vitro .…”

Section: Dopamine Receptor and Cancer Cell Proliferationmentioning

confidence: 99%

The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor

Wang¹,

Wang²,

Luo³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Dopamine receptors are belong to the family of G protein-coupled receptor. There are five types of dopamine receptor (DR), including DRD1, DRD2, DRD3, DRD4, and DRD5, which are divided into two major groups: the D1-like receptors (DRD1 and DRD5), and the D2-like receptors (DRD2, DRD3, and DRD4). Dopamine receptors are involved in all of the physiological functions of dopamine, including the autonomic movement, emotion, hormonal regulation, dopamine-induced immune effects, and tumor behavior, and so on. Increasing evidence shows that dopamine receptors are associated with the regulation of tumor behavior, such as tumor cell death, proliferation, invasion, and migration. Recently, some studies showed that dopamine receptors could regulate several ways of death of the tumor cell, including apoptosis, autophagy-induced death, and ferroptosis, which cannot only directly affect tumor behavior, but also limit tumor progress via activating tumor immunity. In this review, we focus mainly on the function of the dopamine receptor on Bio-behavior of tumor as a potential therapeutic target.

show abstract

“…Gao et al [40] results suggest that DR1 are expressed in the osteosarcoma cells and inhibit the proliferation of osteosarcoma cells by the down-regulation of the ERK1/2 and PI3K-Akt pathways. In a different study, the same research group [41] suggested that activation of DR1 induces osteosarcoma cell apoptosis via changes to the MAPK pathway.…”

Section: Discussionmentioning

confidence: 99%

miRNA deregulation targets specific pathways in leiomyosarcoma development: an in silico analysis

et al. 2019

View full text Add to dashboard Cite

Background: MicroRNA (miRNA) mediate post-transcriptional gene repression and are involved in a variety of human diseases, including cancer. Soft tissue sarcomas are rare malignancies with a variety of histological subtypes which may occur virtually anywhere in the human body. Leiomyosarcoma is one of the most common subtypes, shows a smooth muscle phenotype and its cancerogenesis is still unclear. The aim of our study was to investigate the potential role of miRNA differential expression in leiomyosarcoma development. Methods: We first employed the Sarcoma microRNA Expression Database, a repository that describes the patterns of over 1000 miRNA expression in various human sarcoma types, to identify differentially expressed miRNA comparing leiomyosarcoma and smooth muscle samples. Subsequently, we identified putative target genes of those miRNAs with the TargetScan prediction tool. Finally, we evaluated whether the retrieved pool of putative targets was enriched in genes belonging to specific molecular pathways by means of the Enrichr analysis tool. Protein-protein network analysis was analyzed by means of the STRING web tool. Results: Out of 1120 miRNAs tested, the expression of 301 miRNAs was statistically significantly different between leiomyosarcoma and smooth muscle samples. The hypothetical targets could be predicted for 172 miRNAs. 438 genes were predicted to be the targets with high confidence (cumulative weighted context score cutoff level less than − 1.0) and analyzed for belonging to specific molecular pathways. Pathway analysis suggested that RNA Polymerase III, tRNA functions and synaptic neurotransmission (with special regard to dopamine mediated signaling) could be involved in leiomyosarcoma development. Conclusions: Our results demonstrate that data mining of publicly available repositories can be useful to suggest molecular pathways underlying the pathogenesis of rare tumors such as leiomyosarcoma.

show abstract

The effect and mechanism of dopamine D1 receptors on the proliferation of osteosarcoma cells

Cited by 17 publications

References 24 publications

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies

The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor

miRNA deregulation targets specific pathways in leiomyosarcoma development: an in silico analysis

Contact Info

Product

Resources

About